H2-calponin attenuate metastasis in human NSCLC by suppressing RSK2 expression

Area of Science:

• Oncology
• Molecular Biology
• Cancer Metastasis Research

Background:

• Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality, with limited improvement in advanced-stage survival rates.
• Understanding the molecular mechanisms of metastasis is critical for developing effective cancer therapies.
• Identifying key regulatory genes in metastatic pathways presents a significant challenge in NSCLC treatment.

Purpose of the Study:

• To investigate the role of h2-calponin in non-small cell lung cancer (NSCLC) metastasis.
• To identify the molecular pathways regulated by h2-calponin in NSCLC progression.
• To evaluate h2-calponin as a prognostic factor and potential therapeutic target in NSCLC.

Main Methods:

• Immunohistochemistry and overall survival analysis in NSCLC patients.
• In vitro assays (wound healing, transwell) and in vivo metastasis models (vein injection) to assess metastatic ability.
• RNA interference, Rhodamine-phalloidin staining for actin reorganization, and luciferase reporter assays to elucidate molecular mechanisms.

Main Results:

• Low h2-calponin expression is an independent prognostic factor associated with aggressive clinical outcomes in NSCLC.
• Downregulation of h2-calponin enhances tumor migration, invasion, and metastasis, while upregulation reverses this effect.
• The RSK2/HSP27/CREB pathway is activated by h2-calponin down-regulation, driving increased metastatic potential. h2-calponin and RSK2 expression levels are mildly correlated, with combined low h2-calponin/high RSK2 predicting poorer survival.

Conclusions:

• H2-calponin plays a crucial role in regulating NSCLC metastasis.
• A novel pathway involving h2-calponin and RSK2 is identified as a key driver of tumor metastasis in NSCLC.
• This h2-calponin/RSK2 signaling pathway represents a potential therapeutic target for treating advanced NSCLC.